ATE354587T1 - Für den corticotropin-releasing-factor-typ-2- rezeptor (crfr2) spezifische antagonisten - Google Patents

Für den corticotropin-releasing-factor-typ-2- rezeptor (crfr2) spezifische antagonisten

Info

Publication number
ATE354587T1
ATE354587T1 AT99940042T AT99940042T ATE354587T1 AT E354587 T1 ATE354587 T1 AT E354587T1 AT 99940042 T AT99940042 T AT 99940042T AT 99940042 T AT99940042 T AT 99940042T AT E354587 T1 ATE354587 T1 AT E354587T1
Authority
AT
Austria
Prior art keywords
present
antagonist
crfr2
releasing factor
relates
Prior art date
Application number
AT99940042T
Other languages
English (en)
Inventor
Joachim Spiess
Andreas Ruehmann
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of ATE354587T1 publication Critical patent/ATE354587T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99940042T 1998-07-24 1999-07-23 Für den corticotropin-releasing-factor-typ-2- rezeptor (crfr2) spezifische antagonisten ATE354587T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98113896 1998-07-24

Publications (1)

Publication Number Publication Date
ATE354587T1 true ATE354587T1 (de) 2007-03-15

Family

ID=8232340

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99940042T ATE354587T1 (de) 1998-07-24 1999-07-23 Für den corticotropin-releasing-factor-typ-2- rezeptor (crfr2) spezifische antagonisten

Country Status (7)

Country Link
US (1) US6846803B1 (de)
EP (1) EP1100819B1 (de)
AT (1) ATE354587T1 (de)
AU (1) AU765512B2 (de)
CA (1) CA2338561A1 (de)
DE (1) DE69935227T2 (de)
WO (1) WO2000005253A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670140B2 (en) 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
AU2011348220B2 (en) 2010-12-22 2017-09-07 The Salk Institute For Biological Studies Cyclic CRF antagonist peptides
KR20190060642A (ko) * 2017-11-24 2019-06-03 고쿠리츠 다이가쿠 호우징 나고야 다이가쿠 심부전의 예방 또는 치료용 의약

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58183657A (ja) * 1982-04-13 1983-10-26 フア−ミタリア・カルロ・エルバ・ソシエタ・ペル・アツイオ−ニ 生物学的に活性なペプチド
US5464757A (en) * 1991-01-15 1995-11-07 The Salk Institute For Biological Studies DNA encoding CRF binding protein
US5663292A (en) * 1994-12-12 1997-09-02 The Salk Institute For Biological Studies Cyclic CRF analogs

Also Published As

Publication number Publication date
EP1100819A2 (de) 2001-05-23
AU765512B2 (en) 2003-09-18
EP1100819B1 (de) 2007-02-21
WO2000005253A9 (en) 2000-07-27
DE69935227D1 (de) 2007-04-05
US6846803B1 (en) 2005-01-25
DE69935227T2 (de) 2007-10-31
WO2000005253A3 (en) 2000-06-15
AU5413199A (en) 2000-02-14
CA2338561A1 (en) 2000-02-03
WO2000005253A2 (en) 2000-02-03

Similar Documents

Publication Publication Date Title
Whalen et al. Protein synthesis and actin heterogeneity in calf muscle cells in culture.
Luetteke et al. Characterization of high molecular weight transforming growth factor. alpha. produced by rat hepatocellular carcinoma cells
Qin et al. A comparative study of sialic acid‐rich proteins in rat bone and dentin
Cummins et al. Chemical and immunochemical characteristics of tropomyosins from striated and smooth muscle
NZ236511A (en) Polypeptides containing sequences from residues 61 to 82 or 104 to 129 of human il-4 or subsequences thereof; antibodies and pharmaceutical compositions
DE69819345D1 (de) Für den capsaicin rezeptor kodierende nukleinsäuresequenzen und dem capsaicin rezeptor ähnliche polypeptide und ihre verwendung
BR9814335A (pt) Proteìna, exceto as existentes ao natural, polinucleotìdeo substancialmente puro, anticorpo elaborado por um processo que compreende a etapa de injetar uma preparação farmaceuticamente aceitável, vetor para expressar o drr-1 de rato, vetor, célula hospedeira drr-1 de rato, drr-1 de ser humano, drr-2 de ser humano, drr-3 de ser humano, drr-4 de ser humano, drr-5 de ser humano, drr-6 de ser humano recombinantes, e, processo para ensaiar um composto de teste quanto à sua capacidade para ligar-se a ou para ativar um receptor especìfico de gânglios da raiz dorsal ligado à proteìna g (drr)
Rönnstrand et al. Purification of the receptor for platelet-derived growth factor from porcine uterus.
NZ500253A (en) Osteoprotegerin binding proteins and receptors
EP2311955A3 (de) Osteoprotegerin bindende Proteine und deren Rezeptoren
DE69840195D1 (de) Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1
DE69232309D1 (de) Weitgehend reine rezeptorartige, tgf-beta-1-bindende moleküle und deren verwendungen
Sugino et al. Purification and characterization of high molecular weight forms of inhibin from bovine follicular fluid.
DE69636437D1 (de) Ligand polypeptide für hypophyse g-protein gekoppeltes rezeptor-protein, deren herstellung und anwendung
MXPA02008239A (es) Gen humano de la esquizofrenia.
TW272197B (de)
DE69734096D1 (de) Rezeptor des ob-proteins und verwandte zusammensetzungen und verfahren
HK1025793A1 (en) Hepatitis c receptor protein cd81
ATE542138T1 (de) Her-2-bindungsantagonisten
ATE354587T1 (de) Für den corticotropin-releasing-factor-typ-2- rezeptor (crfr2) spezifische antagonisten
WO1994026891A3 (en) Purified mammalian flt3 ligands and agonists and antagonists thereof
CA2329138C (en) Glycoproteins having lipid mobilising properties and therapeutic applications thereof
Lowey et al. Neonatal and adult myosin heavy chains form homodimers during avian skeletal muscle development.
DE69736158D1 (de) Glutamine: Fructose-6-Phosphat Amidotransferase (GFAT), ihre Herstellung und Verwendung
WO2002026930A3 (en) Nucleic acids, proteins, and antibodies

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties